Sugi Predict

Sugi Predict / Compounds / SCHEMBL16280123

SCHEMBL16280123

SCHEMBL16280123

CC[C@@H](OCc1ccccc1)c1oc2ccccc2c(=O)c1-c1cccc(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 5/20 0.50
▸ PIK3CG P48736 2/20 0.50
▸ POLB P06746 2/20 0.42
▸ GABRP O00591 2/20 0.42
▸ GABRD O14764 2/20 0.42
▸ GABRA1 P14867 2/20 0.42
▸ GABRB1 P18505 2/20 0.42
▸ GABRG2 P18507 2/20 0.42
▸ GABRB3 P28472 2/20 0.42
▸ GABRA5 P31644 2/20 0.42
▸ GABRA3 P34903 2/20 0.42
▸ GABRA2 P47869 2/20 0.42
▸ GABRB2 P47870 2/20 0.42
▸ GABRA4 P48169 2/20 0.42
▸ GABRE P78334 2/20 0.42
▸ GABRA6 Q16445 2/20 0.42
▸ GABRG1 Q8N1C3 2/20 0.42
▸ GABRG3 Q99928 2/20 0.42
▸ GABRQ Q9UN88 2/20 0.42
▸ CA1 P00915 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15528091 1.00 PIK3CD (0.50) PIK3CDPIK3CGPOLBGABRPGABRD
SCHEMBL15599697 0.89 PIK3CD (0.48) PIK3CDPIK3CGPOLBGABRPGABRD
SCHEMBL16457905 0.89 PIK3CD (0.48) PIK3CDPIK3CGPOLBGABRPGABRD
SCHEMBL15528080 0.89 PIK3CD (0.48) PIK3CDPIK3CGPOLBGABRPGABRD
SCHEMBL25290052 0.83 PIK3CD (0.54) PIK3CDPIK3CGPOLBGABRPGABRD
SCHEMBL25808416 0.83 PIK3CD (0.54) PIK3CDPIK3CGPOLBGABRPGABRD
SCHEMBL16457581 0.82 PIK3CD (0.46) PIK3CDPIK3CGPOLBGABRPGABRD
SCHEMBL15528157 0.82 PIK3CD (0.46) PIK3CDPIK3CGPOLBGABRPGABRD
SCHEMBL30128663 0.82 PIK3CD (0.55) PIK3CDPIK3CGPOLBGABRPGABRD
SCHEMBL16279066 0.82 PIK3CD (0.55) PIK3CDPIK3CGPOLBGABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023130334-A1 METHOD FOR PREPARING CHROMEN-4-ONE COMPOUND AND INTERMEDIATE THEREOF 同润生物医药(上海)有限公司 2023-07-13 — — WO disclosed
US-11478481-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals RHIZEN PHARMACEUTICALS AG (CH) 2022-10-25 — — US disclosed
US-11466006-B2 Dual selective PI3 delta and gamma kinase inhibitors RHIZEN PHARMACEUTICALS AG (CH) 2022-10-11 — — US disclosed
US-20210032248-A1 DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2021-02-04 — — US disclosed
US-10851107-B2 Dual selective P13 delta and gamma kinase inhibitors RHIZEN PHARMACEUTICALS SA (CH) 2020-12-01 — — US disclosed
EP-2844647-B1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS S A (CH) 2020-07-22 — — EP disclosed
US-20190038634-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS AG (CH) 2019-02-07 — — US disclosed
US-10130635-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals RHIZEN PHARMACEUTICALS SA (CH) 2018-11-20 — — US disclosed
US-20180098994-A9 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS AG (CH) 2018-04-12 — — US disclosed
US-20170334914-A1 DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2017-11-23 — — US disclosed
US-9790224-B2 Dual selective PI3 delta and gamma kinase inhibitors RHIZEN PHARMACEUTICALS SA (CH) 2017-10-17 — — US disclosed
US-20170266196-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS SA (CH) 2017-09-21 — — US disclosed
EP-3004106-B1 DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS RHIZEN PHARMACEUTICALS S A (CH) 2017-08-30 — — EP disclosed
US-9309216-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals RHIZEN PHARMACEUTICALS SA (CH) 2016-04-12 — — US disclosed
US-20150087699-A1 NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS AG (CH) 2015-03-26 — — US disclosed
US-20140364447-A1 DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2014-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190038634-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS CYP4B1, ADH1A, CYP1A2 PIK3CD 516/4885PIK3CG 636/4885POLB 381/4885
US-20150087699-A1 NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS CYP4B1, ADH1A, CYP1A2 PIK3CD 561/4885PIK3CG 735/4885POLB 498/4885
US-20210032248-A1 DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS PRKCZ, PIK3CD, PRKCE PIK3CD 2/4885PIK3CG 9/4885POLB 826/4885
US-11478481-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals CYP4B1, ADH1A, CYP1A2 PIK3CD 516/4885PIK3CG 636/4885POLB 381/4885
US-10851107-B2 Dual selective P13 delta and gamma kinase inhibitors PRKCZ, PRKCH, PRKCG PIK3CD 24/4885PIK3CG 34/4885POLB 1045/4885
US-11466006-B2 Dual selective PI3 delta and gamma kinase inhibitors PRKCZ, PIK3CD, PRKCE PIK3CD 2/4885PIK3CG 9/4885POLB 826/4885
US-20180098994-A9 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS CYP4B1, ADH1A, CYP1A2 PIK3CD 516/4885PIK3CG 636/4885POLB 381/4885
US-20170334914-A1 DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS PRKCZ, PIK3CD, PRKCE PIK3CD 2/4885PIK3CG 9/4885POLB 826/4885
US-20170266196-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS CYP4B1, ADH1A, CYP1A2 PIK3CD 516/4885PIK3CG 636/4885POLB 381/4885
US-20140364447-A1 DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS PRKCZ, PIK3CD, PRKCE PIK3CD 2/4885PIK3CG 9/4885POLB 826/4885
US-10130635-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals CYP4B1, ADH1A, CYP1A2 PIK3CD 516/4885PIK3CG 636/4885POLB 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback